| Stereochemistry | ACHIRAL |
| Molecular Formula | C22H24ClN3OS2 |
| Molecular Weight | 446.028 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
ClC1=CC=C2SC3=CC=CC=C3N(CCCN4CCC5(CC4)NC(=O)CS5)C2=C1
InChI
InChIKey=CFOYBMUYCBSDAL-UHFFFAOYSA-N
InChI=1S/C22H24ClN3OS2/c23-16-6-7-20-18(14-16)26(17-4-1-2-5-19(17)29-20)11-3-10-25-12-8-22(9-13-25)24-21(27)15-28-22/h1-2,4-7,14H,3,8-13,15H2,(H,24,27)
| Molecular Formula | C22H24ClN3OS2 |
| Molecular Weight | 446.028 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
CNS Activity
Originator
Approval Year
PubMed
Sample Use Guides
Treatment with Clospirazine hydrochloride (spiclomazine) for 24 and 48 h resulted in a time and
dose-dependent growth reduction of CFPAC-1 and MIA PaCa-2 cell lines examined
by MTT assay. This small molecule inhibited the
cell growth to approximately 61.1+/-5.3%, 76.4+/-3.2% and
90.4+/-0.5% of control in CFPAC-1 cells, and 79.3+/-1.0%,
84.5+/-1.5% and 93.6+/-0.2% of control in MIA PaCa-2 cells at
the concentrations of 30, 40, and 50 mg/mL for 48 h, respectively.
